Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Loa Davidsdottir"'
Autor:
Erik Hertervig, Sven Almer, Loa Davidsdottir, Leif Angelison, Jan Marsal, Ulf Hindorf, Stefan Lindgren, Per Hammarlund
Publikováno v:
Scandinavian journal of gastroenterology. 55(2)
Objective: Randomized controlled trials have shown the effectiveness of Adalimumab in ulcerative colitis. However, real-life data is scarce. We aimed to assess the effectiveness and predictive fact...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c08a1c29b3e7eb65fed166caad510d7c
https://pubmed.ncbi.nlm.nih.gov/31961234
https://pubmed.ncbi.nlm.nih.gov/31961234
Publikováno v:
Liver International. 35:1862-1871
Background & Aims Surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is recommended in clinical guidelines. In real-life management, surveillance rates below 20% have been reported from the United States. We aimed to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea1c63f48fe7b8fd70dfac237638ce8d
https://doi.org/10.1111/liv.12764
https://doi.org/10.1111/liv.12764
Autor:
Ulf Sundin, Laura Landucci, Loa Davidsdottir, Ann-Charlotte Wikström, Ragnar Befrits, Michael Eberhardson, Per Marits, Jakob Nilsson
Publikováno v:
Journal of Crohn's and Colitis. 8:881-889
The anti-TNF antibody infliximab is effective in inducing remission in Crohn's disease as well as in ulcerative colitis and many patients are treated for several years with sustained clinical remission. However, the role of monitoring s-infliximab an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e2f8b07906d9727f938162da3946687
https://doi.org/10.1016/j.crohns.2014.01.009
https://doi.org/10.1016/j.crohns.2014.01.009
Autor:
Erik Bäck, Soo Aleman, Anna Törner, Rolf Hultcrantz, Anders Blaxhult, Karl Ekdahl, Loa Davidsdottir, Anders Ekbom, Ann-Sofi Duberg
Publikováno v:
Scandinavian Journal of Gastroenterology. 45:944-952
The aim of this nationwide cohort study was to assess the risk for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection or HBV and hepatitis C virus (HCV) co-infection in Sweden, a low endemic country.A total of 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca1ff6da44f4d6aa7d5d94a59b760a2
https://doi.org/10.3109/00365521003770251
https://doi.org/10.3109/00365521003770251
Autor:
Einar Björnsson, Loa Davidsdottir
Publikováno v:
Journal of Hepatology. 50:511-517
Background/Aims Chronic evolution after drug-induced liver injury (DILI) has been reported. How often this leads to liver-related morbidity and mortality is unexplored. Methods Patients who survived DILI and concomitant jaundice reported to the Swedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8078055a15646571eae046a22e1a1cec
https://doi.org/10.1016/j.jhep.2008.10.021
https://doi.org/10.1016/j.jhep.2008.10.021
Autor:
Soo Aleman, Loa Davidsdottir, Fredrik Granath, Nina Rose, Anders Ekbom, Hans Verbaan, Hans Norrgren, Magnus Hedenstierna, Per Stål, Ola Weiland, Rolf Hultcrantz, Nogol Rahbin, Tony Carlsson
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 57(2)
Background. The long-term effect of sustained virologic response (SVR) to antiviral therapy on the risk of developing hepatocellular carcinoma (HCC), liver complications, liver-related death, and overall death in hepatitis C virus (HCV)–infected pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e7f8cb748b8775ca8a115685ea94b4
https://pubmed.ncbi.nlm.nih.gov/23616493
https://pubmed.ncbi.nlm.nih.gov/23616493
Autor:
Karin Hagen, Ola Weiland, Loa Davidsdottir, Antti Oksanen, Markus Birk, Nogol Rahbin, Tony Carlsson, Eliya Syed, Soo Aleman, Rolf Hultcrantz
Publikováno v:
Scandinavian journal of gastroenterology. 43(11)
Pegylated interferon (peg-IFN) and ribavirin (RBV) treatment is less effective in patients with hepatitis C virus (HCV) and liver cirrhosis than in non-cirrhotic patients. Many patients with advanced liver disease have been excluded from the pivotal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7156a3df997c832b1aabf563b14c59d5
https://pubmed.ncbi.nlm.nih.gov/18615358
https://pubmed.ncbi.nlm.nih.gov/18615358